Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Oxytocin is an anabolic bone hormone.

Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, Patano N, Strippoli M, Vergari R, Mancini L, Colucci S, Grano M, Faccio R, Liu X, Li J, Usmani S, Bachar M, Bab I, Nishimori K, Young LJ, Buettner C, Iqbal J, Sun L, Zaidi M, Zallone A.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7149-54. doi: 10.1073/pnas.0901890106. Epub 2009 Apr 15.

2.

Oxytocin and bone.

Colaianni G, Sun L, Zaidi M, Zallone A.

Am J Physiol Regul Integr Comp Physiol. 2014 Oct 15;307(8):R970-7. doi: 10.1152/ajpregu.00040.2014. Epub 2014 Sep 10. Review.

3.

The oxytocin-bone axis.

Colaianni G, Tamma R, Di Benedetto A, Yuen T, Sun L, Zaidi M, Zallone A.

J Neuroendocrinol. 2014 Feb;26(2):53-7. doi: 10.1111/jne.12120. Review.

4.

Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton.

Colaianni G, Sun L, Di Benedetto A, Tamma R, Zhu LL, Cao J, Grano M, Yuen T, Colucci S, Cuscito C, Mancini L, Li J, Nishimori K, Bab I, Lee HJ, Iqbal J, Young WS 3rd, Rosen C, Zallone A, Zaidi M.

J Biol Chem. 2012 Aug 17;287(34):29159-67. doi: 10.1074/jbc.M112.365049. Epub 2012 Jul 2.

5.

Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis.

Elabd C, Basillais A, Beaupied H, Breuil V, Wagner N, Scheideler M, Zaragosi LE, Massiéra F, Lemichez E, Trajanoski Z, Carle G, Euller-Ziegler L, Ailhaud G, Benhamou CL, Dani C, Amri EZ.

Stem Cells. 2008 Sep;26(9):2399-407. doi: 10.1634/stemcells.2008-0127. Epub 2008 Jun 26.

7.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

8.

Oxytocin deficiency impairs maternal skeletal remodeling.

Liu X, Shimono K, Zhu LL, Li J, Peng Y, Imam A, Iqbal J, Moonga S, Colaianni G, Su C, Lu Z, Iwamoto M, Pacifici M, Zallone A, Sun L, Zaidi M.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):161-6. doi: 10.1016/j.bbrc.2009.07.148. Epub 2009 Aug 3.

PMID:
19653998
9.

Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.

Kim JY, Cheon YH, Kwak SC, Baek JM, Yoon KH, Lee MS, Oh J.

J Bone Miner Res. 2014 Jul;29(7):1541-53. doi: 10.1002/jbmr.2183.

10.

12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.

Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.

J Bone Miner Res. 2003 Dec;18(12):2159-68.

11.

Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts.

Colaianni G, Di Benedetto A, Zhu LL, Tamma R, Li J, Greco G, Peng Y, Dell'Endice S, Zhu G, Cuscito C, Grano M, Colucci S, Iqbal J, Yuen T, Sun L, Zaidi M, Zallone A.

Biochem Biophys Res Commun. 2011 Aug 5;411(3):512-5. doi: 10.1016/j.bbrc.2011.06.158. Epub 2011 Jun 29.

PMID:
21741363
12.

IL-1 plays an important role in the bone metabolism under physiological conditions.

Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y.

Int Immunol. 2010 Oct;22(10):805-16. doi: 10.1093/intimm/dxq431. Epub 2010 Aug 2.

PMID:
20679512
13.

Peripheral cannabinoid receptor, CB2, regulates bone mass.

Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I.

Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701. Epub 2006 Jan 9.

14.

The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis.

Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K.

J Bone Miner Res. 2010 Apr;25(4):809-18. doi: 10.1359/jbmr.091030.

15.
16.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
17.

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH.

J Biol Chem. 2006 Aug 18;281(33):23698-711. Epub 2006 Jun 20.

18.

A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.

Kim HJ, Yoon KA, Lee MK, Kim SH, Lee IK, Kim SY.

Life Sci. 2012 Nov 2;91(19-20):928-34. doi: 10.1016/j.lfs.2012.09.009. Epub 2012 Sep 20.

PMID:
23000100
19.

Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase.

Chikazu D, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T, Kumegawa M, Nakamura K, Kawaguchi H.

J Biol Chem. 2000 Oct 6;275(40):31444-50.

20.

Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.

Kim MH, Ryu SY, Bae MA, Choi JS, Min YK, Kim SH.

Food Chem Toxicol. 2008 Nov;46(11):3375-82. doi: 10.1016/j.fct.2008.08.016. Epub 2008 Aug 26.

PMID:
18786594

Supplemental Content

Support Center